American Cancer Society (2013) Cancer Facts & Figures 2013. Atlanta: American Cancer Society.Google Scholar
Bleyer, A. and H. G. Welch (2012) “Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence,” New England Journal of Medicine, 367(21):1998–2005.CrossrefWeb of ScienceGoogle Scholar
Chu, K. C., C. R. Smart and R. E. Tarone (1988) “Analysis of Breast Cancer Mortality and Stage Distribution by Age for the Health Insurance Plan Clinical Trial,” Journal of the National Cancer Institute, 80(14):1125–1132.PubMedCrossrefGoogle Scholar
Citarda, F., G. Tomaselli, R. Capocaccia, S. Barcherini, M. Crespi and I. M. S. Group (2001) “Efficacy in Standard Clinical Practice of Colonoscopic Polypectomy in Reducing Colorectal Cancer Incidence,” Gut, 48(6):812–815.PubMedCrossrefGoogle Scholar
German, R. R., A. K. Fink, M. Heron, S. L. Stewart, C. J. Johnson, J. L. Finch and D. Yin (2011) “The Accuracy of Cancer Mortality Statistics Based on Death Certificates in the United States,” Cancer Epidemiology, 35(2):126–131.CrossrefWeb of SciencePubMedGoogle Scholar
Goldman, D. P., C. Gupta, E. Vasudeva, K. Trakas, R. Riley, D. Lakdawalla, D. Agus, N. Sood, A. B. Jena and T. J. Philipson (2013) “The Value of Diagnostic Testing in Personalized Medicine,” Forum for Health Economics and Policy, 16:S87–S99.Google Scholar
Lakdawalla, D. N., E. C. Sun, A. B. Jena, C. M. Reyes, D. P. Goldman and T. J. Philipson (2010) “An Economic Evaluation of the War on Cancer,” Journal of Health Economics, 29(3):333–346.Web of SciencePubMedCrossrefGoogle Scholar
Leaf, C. (2004) “Why We’re Losing The War on Cancer (and How to Win It),” Fortune (European Edition), 149(5):42–55.Google Scholar
National Cancer Institute. Overview of the SEER Program. Retrieved May 2, 2014, from http://seer.cancer.gov/about/overview.html.
Pharmaceutical Research and Manufacturers of America (2013) 2013 Biopharmaceutical Research Industry Profile. Washington, DC: PhRMA.Google Scholar
Philipson, T., M. Eber, D. N. Lakdawalla, M. Corral, R. Conti and D. P. Goldman (2012) “An Analysis of Whether Higher Health Care Spending in the United States versus Europe is ‘worth it’ in the Case of Cancer,” Health Affairs (Millwood), 31(4):667–675.CrossrefGoogle Scholar
Seabury, S. A., D. P. Goldman, J. R. Maclean, J. R. Penrod and D. N. Lakdawalla (2012) “Patients Value Metastatic Cancer Therapy More Highly Than Is Typically Shown Through Traditional Estimates,” Health Affairs, 31(4):691–699.CrossrefWeb of ScienceGoogle Scholar
Shapiro, S., J. D. Goldberg and G. B. Hutchison (1974). “Lead Time in Breast Cancer Detection and Implications for Periodicity of Screening,” American Journal of Epidemiology, 100(5):357–366.PubMedCrossrefGoogle Scholar
Sharma, P., K. Wagner, J. D. Wolchok and J. P. Allison (2011) “Novel Cancer Immunotherapy Agents with Survival Benefit: Recent Successes and Next Steps,” Nature Reviews Cancer, 11(11):805–812.PubMedWeb of ScienceCrossrefGoogle Scholar
Sun, E., A. B. Jena, D. Lakdawalla, C. Reyes, T. J. Philipson and D. P. Goldman (2010) “The Contributions of Improved Therapy and Early Detection to Cancer Survival Gains, 1988-2000,” Forum for Health Economics and Policy, 13(2): DOI: 10.2202/1558-9544.1195.Google Scholar
Taylor Jr., D. H., V. Hasselblad, S. J. Henley, M. J. Thun and F. A. Sloan (2002). “Benefits of Smoking Cessation for Longevity,” American Journal of Public Health, 92(6):990–996.PubMedCrossrefGoogle Scholar
US Department of Health and Human Services. (2013) Percentage of Adults Who Receive Colorectal Cancer Screening as Appropriate. Retrieved April 22, 2014, from https://healthmeasures.aspe.hhs.gov/measure/25.
Wickens, M. R. (1972) “A Note On The Use of Proxy Variables,” Econometrica, 759–761.Google Scholar
Winawer, S. J., A. G. Zauber, M. N. Ho, M. J. O’Brien, L. S. Gottlieb, S. S. Sternberg, J. D. Waye, M. Schapiro, J. H. Bond and J. F. Panish (1993) “Prevention of Colorectal Cancer by Colonoscopic Polypectomy,” New England Journal of Medicine, 329(27):1977–1981.CrossrefGoogle Scholar
About the article
Published Online: 2015-11-18
Published in Print: 2016-06-01
Conflict of interest: Support was provided by Celgene Corporation under contract with Precision Health Economics, a health care consultancy. Authors hold the following positions at Precision Health Economics: partner (DPG, TJP, DNL); consultant (SAS); and chief scientific officer (AC). CNG was previously an employee of Precision Health Economics.
Research funding: Support was provided by Celgene Corporation.
Author statement: SAS had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Support was provided by Celgene Corporation under contract with Precision Health Economics, a health care consultancy. Authors hold the following positions at Precision Health Economics: partner (DPG, TJP, DNL); consultant (SAS); and chief scientific officer (AC). CNG was previously an employee of Precision Health Economics. Precision Health Economics maintained all rights to publication subject to a time-limited period for review and comment by Celgene. In addition, ZMK of Celgene Corporation was fully involved with all aspects of this research, including the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.